Hikma Pharmaceuticals PLC HIK

Last Price
1,968.00
Day Change
29.00|1.50%

As of 23/05/2024
11:18:40 BST | GBX  Minimum 15 Minutes Delay.

Bid/OfferDay RangeVolume90d Ave VolMkt Cap
1,968.00 - 1,971.001,940.00 - 1,971.0021,257591,3064.30Bil
Last Close52 Week RangeP/EYield %ISIN
1,939.001,711.00 - 2,222.0028.992.96GB00B0LCW083

Hikma Pharmaceuticals Share Price

Morningstar's Take HIK

Fair Value Estimate

Uncertainty

+ Avg

Economic Moat

None

Total Returns 22/05/2024

 Chg (%)  
Hikma Pharmaceuticals PLC6.66 
FTSE 100 TR GBP4.79
 
Financials
202120222023
more...
Income Statement
Turnover2,553.002,517.002,875.00
Operating Profit597.00482.00604.00
Net Profit420.00191.00192.00
Reported EPS1.810.840.85
Balance Sheet
Current Assets2,094.001,997.002,089.00
Non Current Assets2,278.002,472.002,580.00
Total Assets4,372.004,471.004,680.00
Current Liabilities1,016.001,077.001,339.00
Total Liabilities1,905.002,323.002,471.00
Total Equity2,467.002,148.002,209.00
Cash Flow
Operating Cash Flow767.00640.00866.00
Net Change in Cash113.00-80.0067.00

Regulatory News

DateAuthor Headline
26/09/2019James Gard Job Curtis Backs St James's Place
FTSE 100 wealth manager, which has come under fire for adviser perks recently, is the 20th largest holding in the Silver-rated City of London Investment Trust
28/05/2019James Gard Galliford Try Rejects Bovis Approach
Talks with FTSE 250 housebuilder Bovis to buy Galliford's housebuilding arm have broken down
03/04/2019Emma Simon Investor Views: I Use Shares for Inheritance Planning
Retired investor Peter Charles is hoping his SIPP portfolio will help provide a nest egg for his children and grandchildren
Director Dealings
TradedActionNotifierPriceAmountValue
more...
07/05/2024DMr. Riad Mishlawi1,979.0073614,565.00
12/03/2024Transfer inMr. Mazen Samih Taleb Darwazah0.0026,8120.00
12/03/2024Transfer inMr. Mazen Samih Taleb Darwazah0.0013,9030.00
12/03/2024Transfer inMr. Said Darwazah0.0034,6520.00

Company Profile

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Stock Style

Mid-Blend

Fiscal Year Ends

December

Employees

2,150

Next Event 08/08/2024

Half-Yearly Results
Ratios
Comp
PER (E)28.43
Div Yld (E)2.96
PEG (E)0.00
ROCE10.60
Op Mrgn21.00
EPS Grwth0.22
Dividends
PreviousLatest
more...
Record Date11/08/2322/03/24
Ex-Div10/08/2321/03/24
Paid15/09/2303/05/24
Amnt19.8837.48
Directors
more...
Executive Director, Vice ChairmanMr. Mazen Samih Taleb Darwazah
Non-Executive DirectorMr. Mohammed Ali Khaldoun S Al-Husry
Non-Executive DirectorMr. Douglas Michael Hurt
Executive Director, ChairmanMr. Said Darwazah
Non-Executive DirectorMs. Nina Henderson
Non-Executive DirectorMr. John Julius Castellani
Non-Executive DirectorMs. Cynthia L. Flowers
Non-Executive DirectorDr. Deneen Vojta
Executive Director, Chief Executive OfficerMr. Riad Mishlawi
Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures